Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1‐week regimen of proton pump inhibitor, amoxicillin and clarithromycin
Open Access
- 16 January 2003
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (2), 259-264
- https://doi.org/10.1046/j.1365-2036.2003.01406.x
Abstract
Aim : To investigate the effect of different proton pump inhibitors, S‐mephenytoin 4′‐hydroxylase (CYP2C19) genotype and antibiotic susceptibility on the eradication rate of Helicobacter pylori. Methods : One hundred and eighty‐seven H. pylori‐infected peptic ulcer patients were randomly treated with either rabeprazole (10 mg b.d.) or lansoprazole (30 mg b.d.) plus amoxicillin (750 mg b.d.) and clarithromycin (400 mg b.d.) for 1 week. The antibiotic susceptibility and CYP2C19 genotype (extensive or poor metabolizer) were investigated. Results : The eradication rates in the rabeprazole–amoxicillin–clarithromycin (RAC) and lansoprazole–amoxicillin–clarithromycin (LAC) groups were 75% and 69%, respectively, on an intention‐to‐treat basis, and 80% and 75%, respectively, on a per protocol basis. The eradication rate for clarithromycin‐resistant strains was significantly lower than that for clarithromycin‐sensitive strains (24% vs. 86%, P < 0.05). For clarithromycin‐sensitive strains in the LAC group, there was a tendency for a lower eradication rate in extensive than poor metabolizers. The eradication rate in extensive metabolizers in the RAC group tended to be higher than that in extensive metabolizers in the LAC group (89% vs. 78%, P = 0.079726). Conclusions : The success of the 1‐week proton pump inhibitor–amoxicillin–clarithromycin regimen depends on the susceptibility of H. pylori to clarithromycin. Moreover, differences in CYP2C19 genotype influence the eradication rates of lansoprazole‐based therapy, and the rabeprazole‐based regimen has an advantage especially in extensive metabolizers.This publication has 41 references indexed in Scilit:
- Helicobacter pyloriInfection and the Development of Gastric CancerThe New England Journal of Medicine, 2001
- A placebo‐controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24‐h intragastric acidity and plasma gastrin concentrations in young healthy male subjectsAlimentary Pharmacology & Therapeutics, 1998
- Efficacy of Lansoprazole in Eradicating Helicobacter pylori: A Meta‐AnalysisHelicobacter, 1998
- Triple Therapy with Omeprazole, Amoxicillin and Clarithromycin Is Effective against Helicobacter Pylori Infection in Gastric Ulcer Patients as well as in Duodenal Ulcer PatientsDigestion, 1998
- Effect of Rabeprazole (E3810), a Novel Proton Pump Inhibitor, on Intragastric pH in Healthy Volunteers.The Tohoku Journal of Experimental Medicine, 1998
- A seven‐day Helicobacter pylori treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate.Alimentary Pharmacology & Therapeutics, 1996
- Healing gastric MALT lymphomas by eradicating H pylori?The Lancet, 1993
- Role of Helicobacter pylori in the Pathogenesis of Gastritis, Peptic Ulcer and Gastric CancerScandinavian Journal of Gastroenterology, 1993
- Effect of varying pH on the susceptibility ofCampylobacter pylori to antimicrobial agentsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989
- PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORIThe Lancet, 1988